Literature DB >> 4341999

Adenovirus, parainfluenza virus and respiratory syncytial virus antibodies in the sera of Jamaicans.

R Jennings.   

Abstract

Surveys for respiratory virus antibodies in the Jamaican population have shown that adenovirus, respiratory syncytial virus and parainfluenza types 1 and 3 virus antibodies are acquired early in life. The incidence of haemagglutination-inhibiting antibodies to parainfluenza viruses increases rapidly with age and almost all adults possess parainfluenza type 3 antibody, usually in high titre. Parainfluenza type 1 antibodies are only slightly less common. Complement-fixing antibodies to the adenovirus group were also observed to increase in incidence with age.Complement-fixing antibody to respiratory syncytial virus was less common in Jamaican sera than antibody to the other respiratory viruses described here. The highest titres were observed in the youngest age-group.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4341999      PMCID: PMC2130203          DOI: 10.1017/s0022172400063105

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  18 in total

1.  Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children.

Authors:  R M CHANOCK; H W KIM; A J VARGOSKO; A DELEVA; K M JOHNSON; C CUMMING; R H PARROTT
Journal:  JAMA       Date:  1961-05-27       Impact factor: 56.272

2.  Studies of acute respiratory illnesses caused by respiratory syncytial virus. 2. Epidemiology and assessment of importance.

Authors:  L MCCLELLAND; M R HILLEMAN; V V HAMPARIAN; A KETLER; C M REILLY; D CORNFELD; J STOKES
Journal:  N Engl J Med       Date:  1961-06-08       Impact factor: 91.245

3.  Antigenic analyses of influenza viruses by complement fixation. I. The production of antibodies to the soluble antigen in guinea pigs.

Authors:  F S LIEF; A FABIYI; W HENLE
Journal:  J Immunol       Date:  1958-01       Impact factor: 5.422

4.  Viral respiratory diseases in Nigeria: a serological survey, II. complement fixing antobody levels of adenoviruses, respiratory syncytial virus, psittacosis virus.

Authors:  A N Njoku-Obi; O Ogunbi
Journal:  J Trop Med Hyg       Date:  1966-07

5.  Respiratory viruses in Jamaica: a virologic and, serologic study. 1. Virus isolations and serologic studies on clinical specimens.

Authors:  R Jennings; L S Grant
Journal:  Am J Epidemiol       Date:  1967-11       Impact factor: 4.897

6.  A community study of respiratory infections in the tropics. I. Description of the community and observations on the activity of certain respiratory agents.

Authors:  A S Monto; K M Johnson
Journal:  Am J Epidemiol       Date:  1967-07       Impact factor: 4.897

7.  Respiratory viruses in Jamaica: a virologic and serologic study. 3. Hemagglutination-inhibiting antibodies to type B and C influenza viruses in the sera of Jamaicans.

Authors:  R Jennings
Journal:  Am J Epidemiol       Date:  1968-03       Impact factor: 4.897

8.  Respiratory viruses in Jamaica: a virologic and serologic study. 2. Hemagglutination-inhibiting antibodies to influenza A viruses in the sera of Jamaicans.

Authors:  R Jennings; L S Grant
Journal:  Am J Epidemiol       Date:  1967-11       Impact factor: 4.897

9.  Respiratory syncytial virus infection and its serologic epidemiology.

Authors:  T Suto; N Yano; M Ikeda; M Miyamoto; S Takai; S Shigeta; Y Hinuma; N Ishida
Journal:  Am J Epidemiol       Date:  1965-11       Impact factor: 4.897

10.  Severe and fatal pneumonia in infants and young children associated with adenovirus infections.

Authors:  C CHANY; P LEPINE; M LELONG; T V LE; P SATGE; J VIRAT
Journal:  Am J Hyg       Date:  1958-05
View more
  1 in total

1.  Age-specific prevalence of complement-fixing antibodies to sixteen viral antigens: a computer analysis of 58,500 patients covering a period of eight years.

Authors:  P Ukkonen; T Hovi; C H von Bonsdorff; P Saikku; K Penttinen
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.